Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy.
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Enobosarm (Primary)
- Indications Advanced breast cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors GTx
- 14 Mar 2017 Status changed from active, no longer recruiting to completed.
- 13 Jan 2016 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 13 Jan 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.